Review



igfbp6 protein expression  (Proteintech)


Bioz Verified Symbol Proteintech is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Proteintech igfbp6 protein expression
    Figure 1. The expression of <t>IGFBP6</t> according to WHO grades, IDH status and 1p/19q status in CGGA and TCGA datasets. (a-c) IGFBP6 was significantly increased in WHO IV, IDH wild type and 1p/19q intact glioma samples in TCGA dataset (d-f). IGFBP6 was significantly increased in WHO IV, IDH wild type and 1p/19q intact glioma samples in CGGA dataset. Photographs of immuno histochemical staining of IGFBP6 in different grades of gliomas. Positive cells are stained brown. (g) Diffuse astrocytoma (WHO grade II). (h) Anaplastic astrocytoma (WHO grade III). (i) Glioblastoma multiforme (WHO grade IV). Magnification, x200. *, **, *** and **** indicate P < 0.05, P < 0.01, P < 0.001 and P < 0.0001, respectively.
    Igfbp6 Protein Expression, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 6 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/igfbp6 protein expression/product/Proteintech
    Average 93 stars, based on 6 article reviews
    igfbp6 protein expression - by Bioz Stars, 2026-05
    93/100 stars

    Images

    1) Product Images from "The clinical characteristics and prognostic value of IGFBP6 in glioma."

    Article Title: The clinical characteristics and prognostic value of IGFBP6 in glioma.

    Journal: Neurological research

    doi: 10.1080/01616412.2021.1963620

    Figure 1. The expression of IGFBP6 according to WHO grades, IDH status and 1p/19q status in CGGA and TCGA datasets. (a-c) IGFBP6 was significantly increased in WHO IV, IDH wild type and 1p/19q intact glioma samples in TCGA dataset (d-f). IGFBP6 was significantly increased in WHO IV, IDH wild type and 1p/19q intact glioma samples in CGGA dataset. Photographs of immuno histochemical staining of IGFBP6 in different grades of gliomas. Positive cells are stained brown. (g) Diffuse astrocytoma (WHO grade II). (h) Anaplastic astrocytoma (WHO grade III). (i) Glioblastoma multiforme (WHO grade IV). Magnification, x200. *, **, *** and **** indicate P < 0.05, P < 0.01, P < 0.001 and P < 0.0001, respectively.
    Figure Legend Snippet: Figure 1. The expression of IGFBP6 according to WHO grades, IDH status and 1p/19q status in CGGA and TCGA datasets. (a-c) IGFBP6 was significantly increased in WHO IV, IDH wild type and 1p/19q intact glioma samples in TCGA dataset (d-f). IGFBP6 was significantly increased in WHO IV, IDH wild type and 1p/19q intact glioma samples in CGGA dataset. Photographs of immuno histochemical staining of IGFBP6 in different grades of gliomas. Positive cells are stained brown. (g) Diffuse astrocytoma (WHO grade II). (h) Anaplastic astrocytoma (WHO grade III). (i) Glioblastoma multiforme (WHO grade IV). Magnification, x200. *, **, *** and **** indicate P < 0.05, P < 0.01, P < 0.001 and P < 0.0001, respectively.

    Techniques Used: Expressing, Staining

    Figure 2. The difference of IGFBP6 in four TCGA molecular markers. (a, c) The expression of IGFBP6 was significantly upregulated in mesenchymal subtype in TCGA and CGGA datasets. (b, d) The ROC curves indicated that IGFBP6 expression exhibited highly sensitivity and specificity to predict mesenchymal subtype in TCGA and CGGA datasets. Area under curve (AUC) was 0.831 and 0.858, respectively. (e) Photographs of immunohistochemical staining of IGFBP6 in gliomas with different molecular subtypes. Positive cells are stained brown. Magnification, x200.
    Figure Legend Snippet: Figure 2. The difference of IGFBP6 in four TCGA molecular markers. (a, c) The expression of IGFBP6 was significantly upregulated in mesenchymal subtype in TCGA and CGGA datasets. (b, d) The ROC curves indicated that IGFBP6 expression exhibited highly sensitivity and specificity to predict mesenchymal subtype in TCGA and CGGA datasets. Area under curve (AUC) was 0.831 and 0.858, respectively. (e) Photographs of immunohistochemical staining of IGFBP6 in gliomas with different molecular subtypes. Positive cells are stained brown. Magnification, x200.

    Techniques Used: Expressing, Immunohistochemical staining, Staining

    Figure 3. The gene ontology analysis of IGFBP6. (a, b) Heatmaps show the IGFBP6-related genes in CGGA and TCGA datasets. (c) The IGFBP6 expression was positively related with immune responses, immune cell migration, regulation of JAK-STAT pathway and so on. (d) The IGFBP6 expression was negatively related with the normal physiological functions of neurons and cells.
    Figure Legend Snippet: Figure 3. The gene ontology analysis of IGFBP6. (a, b) Heatmaps show the IGFBP6-related genes in CGGA and TCGA datasets. (c) The IGFBP6 expression was positively related with immune responses, immune cell migration, regulation of JAK-STAT pathway and so on. (d) The IGFBP6 expression was negatively related with the normal physiological functions of neurons and cells.

    Techniques Used: Expressing, Migration

    Figure 4. IGFBP6 related checkpoints and inflammation activities in CGGA and TCGA cohorts. (a, b) IGFBP6 expression was positively correlated with PDCD1, PDCD1L2, HAVCR2 and CD274 expression. (c, d) The relationship between IGFBP6 expression and seven inflammation activities. In pie charts, positive correlations are displayed in green and negative correlations in red. Color intensity and the size of the circle are proportional to the correlation coefficients.
    Figure Legend Snippet: Figure 4. IGFBP6 related checkpoints and inflammation activities in CGGA and TCGA cohorts. (a, b) IGFBP6 expression was positively correlated with PDCD1, PDCD1L2, HAVCR2 and CD274 expression. (c, d) The relationship between IGFBP6 expression and seven inflammation activities. In pie charts, positive correlations are displayed in green and negative correlations in red. Color intensity and the size of the circle are proportional to the correlation coefficients.

    Techniques Used: Expressing

    Figure 5. IGFBP6 was a prognostic factor in glioma patients. (a-f) Kaplan–Meier survival analysis showed that high expression of IGFBP6 indicated a significantly worse OS in all grade glioma patients (p < 0.0001), GBM patients (p = 0.029), IDH mutant patients (p = 0.01) and IDH wild type (p = 0.015) patients in CGGA dataset. The lower level of IGFBP6 significantly increased glioma sensitivity to radiotherapy (p = 0.002) or chemotherapy (p = 0.034) in CGGA dataset. (g-j) Kaplan–Meier survival analysis showed that high expression of IGFBP6 indicated a significantly worse OS in all grade glioma patients (p < 0.0001), GBM patients (p = 0.0061), IDH mutant patients (p = 0.0283) and IDH wild type (p = 0.0037) patients in TCGA dataset.
    Figure Legend Snippet: Figure 5. IGFBP6 was a prognostic factor in glioma patients. (a-f) Kaplan–Meier survival analysis showed that high expression of IGFBP6 indicated a significantly worse OS in all grade glioma patients (p < 0.0001), GBM patients (p = 0.029), IDH mutant patients (p = 0.01) and IDH wild type (p = 0.015) patients in CGGA dataset. The lower level of IGFBP6 significantly increased glioma sensitivity to radiotherapy (p = 0.002) or chemotherapy (p = 0.034) in CGGA dataset. (g-j) Kaplan–Meier survival analysis showed that high expression of IGFBP6 indicated a significantly worse OS in all grade glioma patients (p < 0.0001), GBM patients (p = 0.0061), IDH mutant patients (p = 0.0283) and IDH wild type (p = 0.0037) patients in TCGA dataset.

    Techniques Used: Expressing, Mutagenesis



    Similar Products

    igfbp6 protein expression  (Proteintech)
    93
    Proteintech igfbp6 protein expression
    Figure 1. The expression of <t>IGFBP6</t> according to WHO grades, IDH status and 1p/19q status in CGGA and TCGA datasets. (a-c) IGFBP6 was significantly increased in WHO IV, IDH wild type and 1p/19q intact glioma samples in TCGA dataset (d-f). IGFBP6 was significantly increased in WHO IV, IDH wild type and 1p/19q intact glioma samples in CGGA dataset. Photographs of immuno histochemical staining of IGFBP6 in different grades of gliomas. Positive cells are stained brown. (g) Diffuse astrocytoma (WHO grade II). (h) Anaplastic astrocytoma (WHO grade III). (i) Glioblastoma multiforme (WHO grade IV). Magnification, x200. *, **, *** and **** indicate P < 0.05, P < 0.01, P < 0.001 and P < 0.0001, respectively.
    Igfbp6 Protein Expression, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/igfbp6 protein expression/product/Proteintech
    Average 93 stars, based on 1 article reviews
    igfbp6 protein expression - by Bioz Stars, 2026-05
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    Figure 1. The expression of IGFBP6 according to WHO grades, IDH status and 1p/19q status in CGGA and TCGA datasets. (a-c) IGFBP6 was significantly increased in WHO IV, IDH wild type and 1p/19q intact glioma samples in TCGA dataset (d-f). IGFBP6 was significantly increased in WHO IV, IDH wild type and 1p/19q intact glioma samples in CGGA dataset. Photographs of immuno histochemical staining of IGFBP6 in different grades of gliomas. Positive cells are stained brown. (g) Diffuse astrocytoma (WHO grade II). (h) Anaplastic astrocytoma (WHO grade III). (i) Glioblastoma multiforme (WHO grade IV). Magnification, x200. *, **, *** and **** indicate P < 0.05, P < 0.01, P < 0.001 and P < 0.0001, respectively.

    Journal: Neurological research

    Article Title: The clinical characteristics and prognostic value of IGFBP6 in glioma.

    doi: 10.1080/01616412.2021.1963620

    Figure Lengend Snippet: Figure 1. The expression of IGFBP6 according to WHO grades, IDH status and 1p/19q status in CGGA and TCGA datasets. (a-c) IGFBP6 was significantly increased in WHO IV, IDH wild type and 1p/19q intact glioma samples in TCGA dataset (d-f). IGFBP6 was significantly increased in WHO IV, IDH wild type and 1p/19q intact glioma samples in CGGA dataset. Photographs of immuno histochemical staining of IGFBP6 in different grades of gliomas. Positive cells are stained brown. (g) Diffuse astrocytoma (WHO grade II). (h) Anaplastic astrocytoma (WHO grade III). (i) Glioblastoma multiforme (WHO grade IV). Magnification, x200. *, **, *** and **** indicate P < 0.05, P < 0.01, P < 0.001 and P < 0.0001, respectively.

    Article Snippet: IGFBP6 Monoclonal Antibody (67,567-1-Ig, dilution: 1:200, Proteintech) was used to detect IGFBP6 protein expression.

    Techniques: Expressing, Staining

    Figure 2. The difference of IGFBP6 in four TCGA molecular markers. (a, c) The expression of IGFBP6 was significantly upregulated in mesenchymal subtype in TCGA and CGGA datasets. (b, d) The ROC curves indicated that IGFBP6 expression exhibited highly sensitivity and specificity to predict mesenchymal subtype in TCGA and CGGA datasets. Area under curve (AUC) was 0.831 and 0.858, respectively. (e) Photographs of immunohistochemical staining of IGFBP6 in gliomas with different molecular subtypes. Positive cells are stained brown. Magnification, x200.

    Journal: Neurological research

    Article Title: The clinical characteristics and prognostic value of IGFBP6 in glioma.

    doi: 10.1080/01616412.2021.1963620

    Figure Lengend Snippet: Figure 2. The difference of IGFBP6 in four TCGA molecular markers. (a, c) The expression of IGFBP6 was significantly upregulated in mesenchymal subtype in TCGA and CGGA datasets. (b, d) The ROC curves indicated that IGFBP6 expression exhibited highly sensitivity and specificity to predict mesenchymal subtype in TCGA and CGGA datasets. Area under curve (AUC) was 0.831 and 0.858, respectively. (e) Photographs of immunohistochemical staining of IGFBP6 in gliomas with different molecular subtypes. Positive cells are stained brown. Magnification, x200.

    Article Snippet: IGFBP6 Monoclonal Antibody (67,567-1-Ig, dilution: 1:200, Proteintech) was used to detect IGFBP6 protein expression.

    Techniques: Expressing, Immunohistochemical staining, Staining

    Figure 3. The gene ontology analysis of IGFBP6. (a, b) Heatmaps show the IGFBP6-related genes in CGGA and TCGA datasets. (c) The IGFBP6 expression was positively related with immune responses, immune cell migration, regulation of JAK-STAT pathway and so on. (d) The IGFBP6 expression was negatively related with the normal physiological functions of neurons and cells.

    Journal: Neurological research

    Article Title: The clinical characteristics and prognostic value of IGFBP6 in glioma.

    doi: 10.1080/01616412.2021.1963620

    Figure Lengend Snippet: Figure 3. The gene ontology analysis of IGFBP6. (a, b) Heatmaps show the IGFBP6-related genes in CGGA and TCGA datasets. (c) The IGFBP6 expression was positively related with immune responses, immune cell migration, regulation of JAK-STAT pathway and so on. (d) The IGFBP6 expression was negatively related with the normal physiological functions of neurons and cells.

    Article Snippet: IGFBP6 Monoclonal Antibody (67,567-1-Ig, dilution: 1:200, Proteintech) was used to detect IGFBP6 protein expression.

    Techniques: Expressing, Migration

    Figure 4. IGFBP6 related checkpoints and inflammation activities in CGGA and TCGA cohorts. (a, b) IGFBP6 expression was positively correlated with PDCD1, PDCD1L2, HAVCR2 and CD274 expression. (c, d) The relationship between IGFBP6 expression and seven inflammation activities. In pie charts, positive correlations are displayed in green and negative correlations in red. Color intensity and the size of the circle are proportional to the correlation coefficients.

    Journal: Neurological research

    Article Title: The clinical characteristics and prognostic value of IGFBP6 in glioma.

    doi: 10.1080/01616412.2021.1963620

    Figure Lengend Snippet: Figure 4. IGFBP6 related checkpoints and inflammation activities in CGGA and TCGA cohorts. (a, b) IGFBP6 expression was positively correlated with PDCD1, PDCD1L2, HAVCR2 and CD274 expression. (c, d) The relationship between IGFBP6 expression and seven inflammation activities. In pie charts, positive correlations are displayed in green and negative correlations in red. Color intensity and the size of the circle are proportional to the correlation coefficients.

    Article Snippet: IGFBP6 Monoclonal Antibody (67,567-1-Ig, dilution: 1:200, Proteintech) was used to detect IGFBP6 protein expression.

    Techniques: Expressing

    Figure 5. IGFBP6 was a prognostic factor in glioma patients. (a-f) Kaplan–Meier survival analysis showed that high expression of IGFBP6 indicated a significantly worse OS in all grade glioma patients (p < 0.0001), GBM patients (p = 0.029), IDH mutant patients (p = 0.01) and IDH wild type (p = 0.015) patients in CGGA dataset. The lower level of IGFBP6 significantly increased glioma sensitivity to radiotherapy (p = 0.002) or chemotherapy (p = 0.034) in CGGA dataset. (g-j) Kaplan–Meier survival analysis showed that high expression of IGFBP6 indicated a significantly worse OS in all grade glioma patients (p < 0.0001), GBM patients (p = 0.0061), IDH mutant patients (p = 0.0283) and IDH wild type (p = 0.0037) patients in TCGA dataset.

    Journal: Neurological research

    Article Title: The clinical characteristics and prognostic value of IGFBP6 in glioma.

    doi: 10.1080/01616412.2021.1963620

    Figure Lengend Snippet: Figure 5. IGFBP6 was a prognostic factor in glioma patients. (a-f) Kaplan–Meier survival analysis showed that high expression of IGFBP6 indicated a significantly worse OS in all grade glioma patients (p < 0.0001), GBM patients (p = 0.029), IDH mutant patients (p = 0.01) and IDH wild type (p = 0.015) patients in CGGA dataset. The lower level of IGFBP6 significantly increased glioma sensitivity to radiotherapy (p = 0.002) or chemotherapy (p = 0.034) in CGGA dataset. (g-j) Kaplan–Meier survival analysis showed that high expression of IGFBP6 indicated a significantly worse OS in all grade glioma patients (p < 0.0001), GBM patients (p = 0.0061), IDH mutant patients (p = 0.0283) and IDH wild type (p = 0.0037) patients in TCGA dataset.

    Article Snippet: IGFBP6 Monoclonal Antibody (67,567-1-Ig, dilution: 1:200, Proteintech) was used to detect IGFBP6 protein expression.

    Techniques: Expressing, Mutagenesis